LU-177-PSMA TREATMENT FOR METASTATIC PROSTATE CANCER – CASE EXAMPLES OF MIRACLE RESPONSES

LU-177-PSMA TREATMENT FOR METASTATIC PROSTATE CANCER – CASE EXAMPLES OF MIRACLE RESPONSES

Prostate specific membrane antigen (PSMA) is expressed in unfavorable prostate cancer. PSMA is basis for new diagnostics and theranostics. 177Lu-PSMA radioligand therapy is mainly used for patients with endstage prostate cancer. This report describes two patients: one patient with a multiple recurre...

Full description

Bibliographic Details
Main Authors:	K. Kairemo, T. Joensuu
Format:	Article
Language:	Russian
Published:	State Budget Educational Institute of Higher Professional Education, Rostov State Medical University, Ministry Health of Russian Federation 2018-03-01
Series:	Vestnik Urologii
Subjects:	metastatic prostate cancer prostate specific membrane antigen lu-177-psma
Online Access:	https://www.urovest.ru/jour/article/view/193

Similar Items

177Lu-PSMA-I&T Radioligand Therapy for Treating Metastatic Castration-Resistant Prostate Cancer: A Single-Centre Study in East Asians
by: Ting Bu, et al.
Published: (2022-03-01)

Towards Routine Clinical Use of Dosimetry in [177Lu]Lu-PSMA Prostate Cancer Radionuclide Therapy: Current Efforts and Future Perspectives
by: Rahaf Alsadi, et al.
Published: (2022-07-01)

<sup>177</sup>Lu-PSMA Therapy in Metastatic Castration-Resistant Prostate Cancer
by: Yasemin Sanli, et al.
Published: (2021-04-01)

Intermittent Radioligand Therapy with <sup>177</sup>Lu-PSMA-617 for Oligometastatic Castration-Resistant Prostate Cancer
by: Nicolai Mader, et al.
Published: (2023-09-01)

Preparation and Preliminary Imaging of Novel Albumin-Binding PSMA Ligand ［177Lu］Lu-DOTA-CPN-PSMA
by: LUO Tian-wei, et al.
Published: (2023-12-01)

AlphaBet: Combination of Radium-223 and [177Lu]Lu-PSMA-I&T in men with metastatic castration-resistant prostate cancer (clinical trial protocol)
by: Louise Kostos, et al.
Published: (2022-11-01)

Quality control of [177Lu]Lu-PSMA preparations using HPLC: effect of sample composition and ligand on recovery
by: Else A. Aalbersberg, et al.
Published: (2022-09-01)

Outcome of <sup>177</sup>Lu-PSMA-617 Radioligand Therapy in Chemo-Refractory Patients with Metastatic Castration-Resistant Early-Onset Prostate Cancer
by: Nicolai Mader, et al.
Published: (2021-08-01)

Advances in <sup>177</sup>Lu-PSMA and <sup>225</sup>Ac-PSMA Radionuclide Therapy for Metastatic Castration-Resistant Prostate Cancer
by: Sui Wai Ling, et al.
Published: (2022-10-01)

Comparison of different methods for post-therapeutic dosimetry in [177Lu]Lu-PSMA-617 radioligand therapy
by: Florian Rosar, et al.
Published: (2021-05-01)

Predictive and prognostic potential of pretreatment 68Ga-PSMA PET tumor heterogeneity index in patients with metastatic castration-resistant prostate cancer treated with 177Lu-PSMA
by: Majid Assadi, et al.
Published: (2022-12-01)

Pretherapeutic PSMA PET-Derived Semiquantitative Parameters as Predictors of PSA Response in Patients with mCRPC Receiving [<sup>177</sup>Lu]Lu-PSMA-617 Radioligand Therapy
by: Dheeratama Siripongsatian, et al.

Investigation of image-based lesion and kidney dosimetry protocols for 177Lu-PSMA-I&T therapy with and without a late SPECT/CT acquisition
by: Sandra Resch, et al.
Published: (2023-02-01)

Salvage Radioligand Therapy with Repeated Cycles of <sup>177</sup>Lu-PSMA-617 in Metastatic Castration-Resistant Prostate Cancer with Diffuse Bone Marrow Involvement
by: Daniel Groener, et al.
Published: (2021-08-01)

Optimized Therapeutic <sup>177</sup>Lu-Labeled PSMA-Targeted Ligands with Improved Pharmacokinetic Characteristics for Prostate Cancer
by: Yitian Wu, et al.
Published: (2022-12-01)

Bone marrow impairment during early [177Lu]PSMA-617 radioligand therapy: Haematotoxicity or tumour progression?
by: Felix Kind, et al.
Published: (2022-04-01)

Response and Toxicity to the Second Course of 3 Cycles of <sup>177</sup>Lu-PSMA Therapy Every 4 Weeks in Patients with Metastatic Castration-Resistant Prostate Cancer
by: Sazan Rasul, et al.
Published: (2021-05-01)

Production and Quality Control of [<sup>177</sup>Lu]Lu-PSMA-I&T: Development of an Investigational Medicinal Product Dossier for Clinical Trials
by: Valentina Di Iorio, et al.
Published: (2022-06-01)

Improved quality control of [177Lu]Lu-PSMA I&T
by: Martin Kraihammer, et al.
Published: (2023-03-01)

Baseline [<sup>68</sup>Ga]Ga-PSMA-11 PET/CT before [<sup>177</sup>Lu]Lu-PSMA-617 Radioligand Therapy: Value of PSMA-Uptake Thresholds in Predicting Targetable Lesions
by: Daniel Groener, et al.
Published: (2023-01-01)

<sup>177</sup>Lu-PSMA-617 in Metastatic Castration-Resistant Prostate Cancer: A Review of the Evidence and Implications for Canadian Clinical Practice
by: Kim N. Chi, et al.
Published: (2024-03-01)

Early PSA Change after [<sup>177</sup>Lu]PSMA-617 Radioligand Therapy as a Predicator of Biochemical Response and Overall Survival
by: Felix Kind, et al.
Published: (2021-12-01)

Therapeutic Outcomes of 177Lu-PSMA Targeted Therapy in Patients with Metastatic Castration-Resistant Prostate Cancer: A Single-Center Study
by: Seyed Ali Mirshahvalad, et al.
Published: (2023-01-01)

Improving Overall Survival and Quality of Life in Patients with Prostate Cancer and Neuroendocrine Tumors Using <sup>177</sup>Lu-iPSMA and <sup>177</sup>Lu-DOTATOC: Experience after 905 Treatment Doses
by: Myrna Luna-Gutiérrez, et al.
Published: (2023-07-01)

[<sup>177</sup>Lu]Lu-PSMA-617 (Pluvicto<sup>TM</sup>): The First FDA-Approved Radiotherapeutical for Treatment of Prostate Cancer
by: Ute Hennrich, et al.
Published: (2022-10-01)

An exceptional response to 177LuPSMA undermined by neuroendocrine transformation
by: Pretoria Bilinski, et al.
Published: (2021-01-01)

Impact of [<sup>177</sup>Lu]Lu-PSMA-617 Radioligand Therapy on Reference Organ Uptake Assessed by [<sup>68</sup>Ga]Ga-PSMA-11-PET/CT
by: Daniel Groener, et al.
Published: (2023-07-01)

Optimization of the radiation dosimetry protocol in Lutetium-177-PSMA therapy: toward clinical implementation
by: Steffie M. B. Peters, et al.
Published: (2023-01-01)

Renal Safety of [<sup>177</sup>Lu]Lu-PSMA-617 Radioligand Therapy in Patients with Compromised Baseline Kidney Function
by: Florian Rosar, et al.
Published: (2021-06-01)

Estimation of relative biological effectiveness of 225Ac compared to 177Lu during [225Ac]Ac-PSMA and [177Lu]Lu-PSMA radiopharmaceutical therapy using TOPAS/TOPAS-nBio/MEDRAS
by: Mikhail Rumiantcev, et al.
Published: (2023-09-01)

A Single Dose of Novel PSMA-Targeting Radiopharmaceutical Agent [<sup>177</sup>Lu]Ludotadipep for Patients with Metastatic Castration-Resistant Prostate Cancer: Phase I Clinical Trial
by: Dongho Shin, et al.
Published: (2022-12-01)

Pre- and intratherapeutic predictors of overall survival in patients with advanced metastasized castration-resistant prostate cancer receiving Lu-177-PSMA-617 radioligand therapy
by: Robin Wrenger, et al.
Published: (2022-07-01)

Replacing Lu-177 with Tb-161 in DOTA-TATE and PSMA-617 therapy: potential dosimetric implications for activity selection
by: Frederik A. Verburg, et al.
Published: (2023-11-01)

Evolving Castration Resistance and Prostate Specific Membrane Antigen Expression: Implications for Patient Management
by: Katharina Kessel, et al.
Published: (2021-07-01)

Quantitative imaging for 177Lu-PSMA treatment response monitoring and dosimetry
by: Catherine Meyer, et al.
Published: (2023-12-01)

Hematological Toxicity in Mice after High Activity Injections of <sup>177</sup>Lu-PSMA-617
by: Amanda Kristiansson, et al.
Published: (2022-03-01)

Stability in the production and transport of 177Lu labelled PSMA
by: Cristian Antonio Wieczorek Villas Boas, et al.
Published: (2021-03-01)

Tubarial salivary glands on PSMA ligands based PET imaging and post 177Lu PSMA therapy scan: reiterating its importance
by: Srinivas Kumar, et al.
Published: (2024-01-01)

Tolerability of concurrent external beam radiotherapy and [177Lu]Lu-PSMA-617 for node-positive prostate cancer in treatment naïve patients, phase I study (PROQURE-I trial)
by: Esmée C. A. van der Sar, et al.
Published: (2023-03-01)

Hematotoxicity and Nephrotoxicity in Prostate Cancer Patients Undergoing Radioligand Therapy with [<sup>177</sup>Lu]Lu-PSMA I&T
by: Philipp E. Hartrampf, et al.
Published: (2022-01-01)